UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 1 TO
FORM 10-Q/A
(mark one)
[X] Quarterly Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
For Quarterly Period Ended March 31, 2002
or
[ ] Transition Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
For Transition Period from __________ to __________
Commission File No. 0-14710
XOMA LTD.
(Exact Name of Registrant as specified in its charter)
Bermuda 52-2154066
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
2910 Seventh Street, Berkeley, CA 94710
(Address of principal executive offices) (Zip Code)
(510) 644-1170
(Registrant's telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X No ___
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Common shares US$.0005 par value 70,287,972
Class Outstanding at March 31, 2002
<page>
PART II - OTHER INFORMATION
Item 6 Exhibits and Reports on Form 8-K.
a) Exhibits:
Exhibit 10.39A Amendment No. 1 to the
Process Development and
Manufacturing Agreement by and
between XOMA (US) LLC and Onyx
Pharmaceuticals, Inc., dated as of
April 15, 2002 (with certain
confidential information omitted,
which omitted information is the
subject of a confidential treatment
request and has been filed
separately with the Securities and
Exchange Commission).1
Exhibit 10.43 License Agreement by and
between XOMA Ireland Limited and
MorphoSys AG, dated as of February
1, 2002 (with certain confidential
information omitted, which omitted
information is the subject of a
confidential treatment request and
has been filed separately with the
Securities and Exchange Commission).
b) Reports on Form 8-K: None.
- ----------
1 Previously filed.
-1-
<page>
XOMA Ltd.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
XOMA LTD.
Date: December 4, 2002 By: /s/ JOHN L. CASTELLO
---------------------------------------
John L. Castello
Chairman of the Board, President and
Chief Executive Officer
Date: December 4, 2002 By: /s/ PETER B. DAVIS
---------------------------------------
Peter B. Davis
Vice President, Finance and
Chief Financial Officer
-2-